Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 10/20 | 0.36 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1439326 | 0.91 | MLYCD (0.33) | MLYCDLMNASMN1; SMN2UTS2RAR | |
| SCHEMBL1948093 | 0.90 | MLYCD (0.35) | MLYCDLMNASMN1; SMN2UTS2RHTT | |
| SCHEMBL1947495 | 0.89 | LMNA (0.34) | MLYCDLMNASMN1; SMN2 | |
| SCHEMBL1949940 | 0.88 | LMNA (0.35) | LMNASMN1; SMN2 | |
| SCHEMBL1950273 | 0.88 | MT-CO2 (0.35) | LMNASMN1; SMN2 | |
| SCHEMBL1947563 | 0.87 | SMN1; SMN2 (0.32) | LMNASMN1; SMN2MAPTTSHRALDH1A1 | |
| SCHEMBL1440585 | 0.87 | MLYCD (0.39) | MLYCDLMNASMN1; SMN2UTS2RMAPT | |
| SCHEMBL1949957 | 0.84 | TSPO (0.35) | LMNASMN1; SMN2HTTARMAPT | |
| SCHEMBL1438384 | 0.83 | MLYCD (0.39) | MLYCDRXRANR1H2NR1H3LMNA | |
| SCHEMBL1439329 | 0.81 | AR (0.32) | MLYCDLMNASMN1; SMN2AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | MERCK SHARP & DOHME LLC | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110135650-A1 | MORPHOLINONE COMPOUNDS AS FACTOR IXA INHIBITORS | SERPINC1, F9, F8 | MLYCD 3443/4885RXRA 1411/4885NR1H2 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.